A Randomized, Open-Label Study of the Effect of PEGASYS [peginterferon alfa-2a] and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naive Patients With Chronic Hepatitis C Genotype 2 or 3 Infection

Trial Profile

A Randomized, Open-Label Study of the Effect of PEGASYS [peginterferon alfa-2a] and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naive Patients With Chronic Hepatitis C Genotype 2 or 3 Infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms ACCELERATE
  • Sponsors Roche
  • Most Recent Events

    • 20 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top